Vantage logo

Reading Arcus’s Tigit tea leaves

As data non-disclosure prompts sellside guesswork one indisputable fact stands out: Gilead has not opted in to Arcus’s domvanalimab.

Vantage logo

CD47 is worth $4.9bn to Gilead

A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.

Vantage logo

Forty Seven bucks the trend

Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.